within Pharmacolibrary.Drugs.ATC.L;

model L04AG08
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.8333333333333335e-06,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00311,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00249,
    k12             = 0.29,
    k21             = 0.29
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AG08</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ocrelizumab is a humanized monoclonal antibody targeting CD20-positive B-cells, used for the treatment of relapsing and primary progressive forms of multiple sclerosis (MS). It is approved by regulatory agencies including the FDA and EMA.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic data in adult MS patients, both sexes, typically aged 18-55 years, with normal renal and hepatic function.</p><h4>References</h4><ol><li><p>Newsome, SD, et al., &amp; Bermel, RA (2024). Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. <i>Annals of clinical and translational neurology</i> 11(12) 3215–3226. DOI:<a href=\"https://doi.org/10.1002/acn3.52229\">10.1002/acn3.52229</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39460719/\">https://pubmed.ncbi.nlm.nih.gov/39460719</a></p></li><li><p>Stahnke, AM, &amp; Holt, KM (2018). Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis. <i>The Annals of pharmacotherapy</i> 52(5) 473–483. DOI:<a href=\"https://doi.org/10.1177/1060028017747635\">10.1177/1060028017747635</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29232960/\">https://pubmed.ncbi.nlm.nih.gov/29232960</a></p></li><li><p>Reichert, JM (2015). Antibodies to watch in 2015. <i>mAbs</i> 7(1) 1–8. DOI:<a href=\"https://doi.org/10.4161/19420862.2015.988944\">10.4161/19420862.2015.988944</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25484055/\">https://pubmed.ncbi.nlm.nih.gov/25484055</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AG08;
